Physician
Infectious Disease
Dr. John R. Mascola, MD
|
|
Give Review
Doctor John R. Mascola, MD is an expert in the field of Infectious Disease. He studied medicine at Georgetown University School of Medicine. Georgetown University School of Medicine is ranked 49/84 in Research/PrimaryCare. He over the years received 1 awards: "Elected Member". John Mascola is also published. He has 98 publications published. The lastest publication: "Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.'
Publications
- In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates.
- Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.
- HIV-1 monoclonal antibodies suppress acute SHIV viremia and limit seeding of cell-associated viral reservoirs.
- Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies.
- Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development.
- Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site.
- Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.
- HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies.
- Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 Env.
- Sustained delivery of a broadly neutralizing antibody in non-human primates confers long-term protection against SHIV infection.
- Eliminating antibody polyreactivity through addition of N-linked glycosylation.
- Correction for Acharya et al., Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements ...
- Correction for Chakrabarti et al., Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates.
- Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.
- Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes.
- Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, rando...
- Structure and immune recognition of trimeric pre-fusion HIV-1 Env.
- Hyperglycosylated stable core immunogens designed to present the CD4 binding site preferentially recognized by broadly neutralizing antibodies.
- Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.
- Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.
- Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.
- Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies.
- DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild Type Glycoproteins are Safe and Immunogenic in a Phase I Clinical Trial.
- HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile.
- IMPACT OF CLADE, GEOGRAPHY AND AGE OF THE EPIDEMIC ON HIV-1 NEUTRALIZATION BY ANTIBODIES.
- Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.
- Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.
- Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
- Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline.
- Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
- Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies.
- Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.
- Structural Basis for HIV-1 Neutralization by 2F5-like Antibodies m66 and m66.6.
- Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
- De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts.
- Isolation of human monoclonal antibodies from peripheral blood B cells.
- A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling.
- Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Non-human Primates.
- Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains.
- Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding ...
- Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.
- HIV-1 neutralizing antibodies: understanding nature's pathways.
- Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies.
- Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
- Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.
- Structural Basis for Highly Effective HIV-1 Neutralization by CD4-Mimetic Miniproteins Revealed by 1.5Â Ã Cocrystal Structure of gp120 and M48U1.
- Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains.
- Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.
- Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization.
- N332-Directed Broadly Neutralizing Antibodies Use Diverse Modes of HIV-1 Recognition: Inferences from Heavy-Light Chain Complementation of Function.
- Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial.
- Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2.
- Outer domain of HIV-1 gp120: Antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.
- Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.
- Anti-HIV B Cell lines as candidate vaccine biosensors.
- Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.
- Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies.
- A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies.
- Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates.
- The changing face of HIV vaccine research.
- Antibody-Dependent Cellular Cytotoxicity Against Primary HIV-Infected CD4+ T Cells is Directly Associated with the Magnitude of Surface IgG Binding.
- HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes.
- Biochemically defined HIV-1 Env variant immunogens display differential binding and neutralizing specificities to the CD4 binding site.
- Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
- Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.
- Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-infected Individuals.
- Structure-Based Identification and Neutralization Mechanism of Tyrosine Sulfate Mimetics That Inhibit HIV-1 Entry.
- Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors.
- TRIM5 modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys.
- Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
- Antibody-Dependent Cell-Mediated Viral Inhibition Emerges after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys Coincident with gp140-Binding Antib...
- Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys.
- Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys.
- Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies.
- Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.
- Genital tract sequestration of SIV following acute infection.
- Early Short-Term Antiretroviral Therapy Is Associated with a Reduced Prevalence of CD8(+)FoxP3(+) T Cells in Simian Immunodeficiency Virus-Infected Controller Rhesus M...
- Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys.
- Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency...
- Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.
- Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.
- Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
- Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neut...
- Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.
- The role of antibodies in HIV vaccines.
- Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.
- Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.
- Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates.
- Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.
- Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.
- Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.
- Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.
- Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1.
- T-cell vaccination reduces simian immunodeficiency virus levels in semen.
- Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys.
- Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.
- The cat and mouse of HIV-1 antibody escape.
Schools
Georgetown University
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- Elected Member
Education
-
Naval Medical Center -
Georgetown University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Netanya S. Utay, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adriana R. Marques, MD |
|
|
Dr. Cheryl L. McDonald, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas J. Vietri, MD |
|
|
Dr. Cindy Tamminga, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John W. Sanders III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janine R. Danko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip E. Coyne Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael C. Sneller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Irini Sereti, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tara Palmore, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barney S. Graham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shruthi Bellapu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey P. Nadler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James G. Kane, MD |
|
|
Dr. Kerry E. Wilson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gerald E. Poley Jr., MD
This Doctor is OpenDoctor Recommended.
|